Tuesday, June 7, 2022, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Multiple Myeloma

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Continental Ballroom – Section C (Lobby Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Ajai Chari, MD
Professor of Medicine (Hematology and Medical Oncology)
Icahn School of Medicine at Mount Sinai
Director, Clinical Research, Multiple Myeloma Program
Associate Medical Director
The Tisch Cancer Institute Clinical Trials Office
New York, New York

Elizabeth O’Donnell, MD
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts


Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

MODULE 1: Front-Line and Maintenance Treatment Options for Patients with Multiple Myeloma (MM)

  • Long-term findings with daratumumab-containing front-line regimens for newly diagnosed MM in patients who are eligible and ineligible for transplant
  • Published data with novel daratumumab-based quadruplet regimens (eg, RVd/daratumumab, KRd/daratumumab) for transplant-eligible newly diagnosed MM
  • Key efficacy and safety findings from the Phase III GMMG-HD7 trial comparing isatuximab in combination with RVd to RVd alone for transplant-eligible patients with newly diagnosed MM; implications for clinical practice
  • Current utility of carfilzomib as a component of up-front therapy; implications of findings from published studies evaluating carfilzomib-based induction therapy
  • Key data from the Phase III DETERMINATION trial examining the timing of stem cell transplant in newly diagnosed MM
  • Selection of an optimal maintenance approach for transplant-eligible and transplant-ineligible patients, including those receiving daratumumab-containing induction regimens

MODULE 2: Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) MM

  • Key data sets supporting the use of selinexor combined with dexamethasone or bortezomib/dexamethasone for patients with R/R MM; early findings with other selinexor-based combinations
  • Principal findings with belantamab mafodotin alone and in combination with other systemic therapies for R/R MM; ongoing evaluations and incorporation into routine practice
  • Published Phase III research with isatuximab for R/R MM (eg, ICARIA-MM, IKEMA trials)
  • Design, eligibility criteria and updated efficacy and safety results from the pivotal Phase II KarMMa trial evaluating idecabtagene vicleucel for R/R MM
  • Key research (eg, CARTITUDE-1, CARTITUDE-2) documenting the effectiveness of ciltacabtagene autoleucel for patients with pretreated MM
  • Incidence, severity and management of toxicities commonly observed with novel therapies for R/R MM

MODULE 3: Future Directions in the Management of MM

  • Similarities and differences in the cellular targets and mechanisms of action of bispecific antibodies under clinical development for R/R MM
  • Antitumor activity and safety observed with various anti-BCMA bispecific antibodies (eg, teclistamab, elranatamab, REGN5458, TNB-383B) in heavily pretreated MM; FDA breakthrough therapy designation for teclistamab
  • Published research findings with novel non-BCMA-targeted bispecific antibodies (eg, talquetamab, cevostamab)
  • Biologic rationale for targeting Bcl-2 in MM; published data with and ongoing investigations of venetoclax-based therapy for patients with MM and t(11;14) or Bcl-2 overexpression
  • Similarities and differences between CELMoDs (eg, iberdomide, mezigdomide) and standard immunomodulatory drugs; activity and safety observed with iberdomide and with mezigdomide in patients with heavily pretreated MM
  • Other promising novel agents and strategies in clinical development for MM

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Customize the selection of first-line therapy for individuals with newly diagnosed MM, considering new clinical research findings and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplantation.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM who are eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory MM.
  • Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies in order to facilitate their integration into MM management algorithms.
  • Evaluate the biologic rationale for the use of chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen in MM, and identify patients for whom treatment with this novel approach should be considered and/or recommended.
  • Recall available data with novel agents and strategies under investigation for MM, and counsel appropriate patients about clinical trial availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Chari — Advisory Committee: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Seagen Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Oncoceutics Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Takeda Pharmaceuticals USA Inc. Dr O'Donnell — Advisory Committee: Bristol-Myers Squibb Company; Consulting Agreements: Bristol-Myers Squibb Company, Janssen Biotech Inc, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc. Dr Orlowski — Advisory Committee and Consulting Agreements: AbbVie Inc, BioTheryX Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Neoleukin Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Clinical Research Funding: CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Laboratory Research Funding: Asylia Therapeutics Inc, BioTheryX Inc, Heidelberg Pharma.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room
Continental Ballroom – Section C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 

Thank you for your interest in our CME program taking place in Chicago, IL. At this time ONLINE "IN-PERSON" PREREGISTERATION is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM. Our Onsite Registration Desk will be open at 6:15 AM Central Time on Tuesday, June 7. If you are interested in attending, please visit our registration desk located outside the Continental Ballroom - Salon C (Lobby Level) of the Hilton Chicago hotel (702 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2022 ASCO Annual Meeting website.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Please note, onsite registration does not guarantee meal service which will be based on availability.

Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.